Home / EDCTP
The European & Developing Countries Clinical Trials Partnership (EDCTP) http://www.edctp.org/ funds clinical research to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials. The EDCTP is funding two major CAPRISA studies: CAPRISA 012 and CAPRISA 018 studies.
CAPRISA 012 trial https://www.caprisa.org/Pages/CAPRISAStudies
is a phase I/II trial conducted in two parts; Part A is a double blinded, randomized, placebo- controlled phase I trial assessing the safety and pharmacokinetic profile of the monoclonal antibodies, PGT121 and VRC07-523.LS administered subcutaneously in HIV negative women. Part B is a double blinded, randomized, placebo-controlled trial, consisting of two components. Component 1 is a phase I trial assessing the safety and PK of CAP256-VRC26.25.LS, followed by component 2 which is a phase II trial evaluating the optimal bNAb combination(s) from the phase I trials. The overall goal of the CAPRISA 012 trial is to develop a combination of two anti-HIV monoclonal antibodies as a new, safe and effective long-acting HIV prevention technology, principally for women, in order to alter the course of the HIV epidemic in Africa.
CAPRISA 018 study https://www.caprisa.org/Pages/CAPRISAStudies
is a phase I/II trial to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide (TAF) sub-dermal implant for HIV prevention in women. This implant combines two well-established elements; a) TAF, which is a licenced antiretroviral drug widely used in HIV treatment, and b) a sub-dermal implant, which is widely used as a route of administration for contraception.
Three CAPRISA scientists have been awarded EDCTP senior grant fellowships http://www.edctp.org/call/senior-fellowships-4/
• Dr Nesri Padayatchi (PhD)
• Dr Desh Archary (PhD)
• Dr Aida Sivro (PhD)